NEW YORK, April 24, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Mylan, Inc. (NASDAQ: MYL), Boston Scientific Corporation (NYSE: BSX), Zimmer Holdings, Inc. (NYSE: ZMH), Covidien plc (NYSE: COV) and Zoetis Inc. (NYSE: ZTS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1543-100free.
Mylan, Inc. Analyst Notes
On April 18, 2014, Mylan, Inc. (Mylan) reported that Teva's application for an injunction seeking to prevent Mylan's launch of a generic version of Copaxone® has been denied by the Supreme Court Chief Justice Roberts for the second time. The move paves way for the Mylan to receive approval from the U.S. Food and Drug Administration on May 25, 2014. Mylan CEO Heather Bresch, said, "We are pleased with the Chief Justice's decision, and we look forward to introducing the first generic Copaxone® treatment for multiple sclerosis patients in the U.S. at market formation. Mylan remains eligible to receive approval from the U.S. Food and Drug Administration on May 25, 2014." Mylan's stock gained 2.98% to close at $48.32 on April 21, 2014. The full analyst notes on Mylan are available to download free of charge at:
Boston Scientific Corporation Analyst Notes
On April 17, 2014, Boston Scientific Corporation (Boston Scientific) announced that it has scheduled an investor event on May 8, 2014 to provide an update on Company Cardiac Rhythm Management and Electrophysiology initiatives as well as developments and technologies in connection with its attendance at the 2014 Annual Heart Rhythm Society Scientific Session in San Francisco, California. As stated by Boston Scientific, the event will include a Q&A session, and is scheduled to commence at 5:00 p.m. PT and adjourn at approximately 6:30 p.m. PT. The participants at the event will include Mike Mahoney, President and CEO, Dan Brennan, Executive Vice President and CFO, Joe Fitzgerald, Executive Vice President and President, Rhythm Management, Kenneth Stein, M.D., Senior Vice President and Chief Medical Officer, Rhythm Management. The full analyst notes on Boston Scientific are available to download free of charge at:
Zimmer Holdings, Inc. Analyst Notes
On April 7, 2014, Zimmer Spine Inc. (Zimmer Spine), a division of Zimmer Holdings, Inc., announced the U.S. market launch of the Optio-C Anterior Cervical System, a next generation, modular stand-alone cervical device that offers the strength, stability and fusion potential of a traditional ACDF. Commenting on the development, Zimmer Spine's President Steve Healy said, "With plate strength equivalent to a traditional cervical plate, stability through a three-screw fixation design, and fusion delivered by a spacer featuring a load-sharing interface, the Optio-C System takes cervical stand-alone devices to the next level." The full analyst notes on Zimmer Holdings are available to download free of charge at:
Covidien plc Analyst Notes
On April 14, 2014, Covidien plc (Covidien) announced the U.S. Food and Drug Administration 510(k) Clearance for the Kangaroo™ feeding tube with Integrated Real-time Imaging System (IRIS) Technology. The Company informed that the new disposable feeding tube is equipped with camera that enhances patient safety. The Covidien's IRIS technology streams a real-time video back to the Kangaroo IRIS monitor, providing not only the visual aid to clinicians in identifying key areas of a patient's anatomy but also enables saving images from the live stream. Jim Clemmer, President, Medical Supplies, Covidien, said "Covidien is an industry leader in nutritional delivery and enteral feeding devices and products such as the Kangaroo feeding tube with IRIS technology are designed to help improve patient outcomes and set new expectations for medical device product safety and innovation around the world." The full analyst notes on Covidien are available to download free of charge at:
Zoetis Inc. Analyst Notes
On April 21, 2014, the shares of Zoetis Inc. (Zoetis) gained 1.50% to end the day at $29.03. During the session, the Company's shares opened at $28.70 and fluctuated in the range of $28.53 - $29.06. A total of 4.44 million shares changed hands during the day. Over the past 12 months, the shares of Zoetis have decreased 10.95%, compared to the NYSE Composite, which increased 17.07% during the same period. The full analyst notes on Zoetis are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review